{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T17:31:57Z","timestamp":1786555917793,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.therap.2025.11.004","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:33:22Z","timestamp":1763692402000},"page":"318-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Are there gender differences in adverse drug reactions to levodopa? A real-world safety comparison in the global pharmacovigilance database"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6341-6001","authenticated-orcid":false,"given":"Jean-Louis","family":"Montastruc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2025.11.004_bib0085","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.therap.2023.01.007","article-title":"Women, medicine and pharmacology: where do we are now?","volume":"78","author":"Lapeyre-Mestre","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.11.004_bib0090","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1472-8206.2002.00100.x","article-title":"Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France","volume":"16","author":"Montastruc","year":"2002","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2025.11.004_bib0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.therap.2022.10.002","article-title":"Sex differences in adverse drug reactions: are women more impacted?","volume":"78","author":"Lacroix","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.11.004_bib0100","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00415-016-8384-9","article-title":"The relevance of gender in Parkinson's disease: a review","volume":"264","author":"Picillo","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.therap.2025.11.004_bib0105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40120-024-00687-6","article-title":"Sex differences in Parkinson's disease: a narrative value","volume":"14","author":"Cattaneo","year":"2025","journal-title":"Neurol Ther"},{"key":"10.1016\/j.therap.2025.11.004_bib0110","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.11.004_bib0115","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.therap.2023.10.007","article-title":"Drug-induced diseases: a worrying, neglected, preventable, serious and costly epidemic","volume":"79","author":"Montastruc","year":"2024","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.11.004_bib0120","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2025.11.004_bib0125","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2025.11.004_bib0130","series-title":"Goodman and Gilman's the pharmacological basis of therapeutics","article-title":"Treatment of central nervous system degenerative disorders","author":"Robertson","year":"2023"},{"key":"10.1016\/j.therap.2025.11.004_bib0135","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/WNF.0000000000000051","article-title":"Sex differences in the pharmacokinetics of levodopa in elderly patients with Parkinson disease","volume":"37","author":"Kumagai","year":"2014","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.therap.2025.11.004_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0149-7634(86)90029-1","article-title":"Effects of estrogen on the basal ganglia","volume":"10","author":"Van Hartesveldt","year":"1986","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.therap.2025.11.004_bib0145","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.therap.2025.11.004_bib0150","first-page":"S93","article-title":"Dopamine and impulse control disorders in Parkinson's disease","volume":"64","author":"Weintraub","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.therap.2025.11.004_bib0155","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(03)00529-5","article-title":"Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?","volume":"2","author":"Lawrence","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.therap.2025.11.004_bib0160","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00128071-200102060-00001","article-title":"Do women have more adverse drug reactions?","volume":"2","author":"Rademaker","year":"2001","journal-title":"Am J Clin Dermatol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725001465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725001465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:37:10Z","timestamp":1786552630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595725001465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0040595725001465"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2025.11.004","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are there gender differences in adverse drug reactions to levodopa? A real-world safety comparison in the global pharmacovigilance database","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2025.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}